港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

584.227

-3.532-0.60%

涨家数：12

跌家数：19

平家数：3

市盈率：- -

高：589.700

开：587.671

低：576.889

收：587.759

成交量：6,860.00万

成交额：12.69亿

市值：3,573.73亿

流通市值：3,214.95亿

数据加载中...

总览新闻资讯

诺诚健华TRK抑制剂癌症新药在中国获批

医药生物2026年创新药投资逻辑：以DE-RISKING路径锁定创新药高成长机会

医药行业周报：IN VIVO CART：BD热门赛道早期技术具备广阔前景

中信建投证券

医药生物行业周报：2025国谈结果公布关注相关公司投资机会

医药生物行业2026年度投资策略报告：十年创新踏出海征程

一周药闻复盘|CPHI制药在线（2025.12.8-12.12）

和讯投顾冯禄顺：1213创新药接下来怎么走

青少年肥胖减肥难？本土创新药临床试验12周减重超8公斤

国内首款！沛嘉医疗新品获NMPA批准上市

医疗器械商业评论

复星医药携手深圳理工大学共建AI驱动医药研发公共服务平台，项目获深圳市战略性新兴产业资助

复星医药官微

心玮医疗-B(06609.HK)：取消监事会

心玮医疗-B拟以每股港币45.00配发及发行100万股国内股份

药明巨诺换帅，新管理层迎战CAR-T市场机遇与挑战

21世纪经济报道

千亿美元出海“秀肌肉”、“首创”瓶颈“卡脖子”：中国创新药直面“仿创”转型考

沛嘉医疗-B获得NMPA批准，Taurustrio经导管主动脉瓣系统开创中国主动脉反流治疗新纪元

科济药业-B(02171)12月12日斥资389.45万港元回购25万股

智通财经网

同源康医药-B公布董事会成员名单及委员会任职情况

歌礼制药-B(01672)12月12日耗资约437.38万港元回购30万股

耐赋康之后，谁接棒？云顶新耀为千亿市值铺路

河南首家医药上市企业易主江西！获10亿元“输血”的太龙药业

微博财经-财道工作室

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news?page=12"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":584.22656,"timestamp":1766045292012,"preClose":587.75903,"halted":0,"volume":68600038,"delay":0,"changeRate":-0.00601,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-3.532471,"latestTime":"12-18 16:00:00","open":587.6708,"high":589.70044,"low":576.88855,"amount":1269057381,"amplitude":0.021798,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1766021400000,1766030400000],[1766034000000,1766044800000]],"pbRate":4.97274,"peRate":-40.922669,"turnoverRate":0.002491,"increases":10,"decrements":21,"flats":2,"marketCap":357373288832,"floatMarketCap":321494630240},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":589.70044,"amplitude":0.021798,"preClose":587.75903,"low":576.88855,"pbRate":"4.97274","latestPrice":584.22656,"volume":68600038,"delay":0,"open":587.6708,"prevYearClose":331.1933,"prevWeekClose":614.11,"prevMonthClose":632.157,"prevQuarterClose":752.859,"fiveDayClose":595.939,"twentyDayClose":610.919,"sixtyDayClose":730.007,"secType":"PLATE","market":"HK","turnoverRate":0.002491,"peRate":-40.922669,"marketCap":357373288832,"floatMarketCap":321494630240,"timestamp":1766045292012,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":19,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:12,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591765756","title":"诺诚健华TRK抑制剂癌症新药在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2591765756","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591765756?lang=zh_cn&edition=fundamental","pubTime":"2025-12-14 07:31","pubTimestamp":1765668685,"startTime":"0","endTime":"0","summary":"12月11日，诺诚健华宣布，该公司自主研发的新一代TRK抑制剂佐来曲替尼获得中国国家药品监督管理局批准，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。据诺诚健华新闻稿介绍，作为新一代TRK抑制剂，佐来曲替尼不仅能够带来长期深度缓解、且药物透脑活性强、整体安全性良好，同时有数据显示能够克服第一代TRK抑制剂的耐药性。诺诚健华预计不久将递交佐来曲替尼治疗儿童患者的NDA上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214073302a69f6f3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214073302a69f6f3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2591865274","title":"医药生物2026年创新药投资逻辑：以DE-RISKING路径锁定创新药高成长机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865274","media":"天风证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591865274?lang=zh_cn&edition=fundamental","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"中国将持续涌现高质量创新药中国创新药行业已初步形成以龙头企业为引领，大批量优质企业为骨干的金字塔梯队，产学研持续加深合作，产业项目储备多。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214141231a449435c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214141231a449435c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","LU0455707207.USD","HK0000165453.HKD","02171","LU1969619763.USD","01167","BK1161","09969","01801","LU2097828474.EUR","LU2097828631.EUR","06160","LU2097828557.USD","02616","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","06990","02552","BK1583","BK1589","BK1574","LU2328871848.SGD","06978","02105","LU0502904849.HKD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2591657917","title":"医药行业周报：IN VIVO CART：BD热门赛道 早期技术具备广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657917","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591657917?lang=zh_cn&edition=fundamental","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"核心观点：In Vivo CART赛道发展火热，2025年已经有四个MNC并购的案例发生。具体来看，In Vivo CART分为LNP和慢病毒两条技术路线，两条技术路线均具备显著特色。LNP路线来看，药物在临床前展现出了快速转染以及优异的靶向性特点，慢病毒路线中，Esobiotec等公司的BCMA In Vivo CART已经在小人群MM患者中展现非常好的早期数据。整体看，In VivoCART发展迅速，后续发展值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1576","BK1141","01801","LU0320764599.SGD","LU2045819591.USD","06160","06978","BK1583","LU1046422090.SGD","LU2242644610.SGD","LU2125910500.SGD","LU0708995583.HKD","06821","BK1161","02359","LU0052750758.USD","01177"],"gpt_icon":0},{"id":"2591657861","title":"医药生物行业周报：2025国谈结果公布 关注相关公司投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657861","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591657861?lang=zh_cn&edition=fundamental","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"2025 国谈结果重磅公布，关注相关公司投资机会12 月7 日，国家医保局重磅发布2025 年医保谈判结果，此外还首次同步启动了商保目录的制定工作。2025 医保目录新增114 种药品，总体成功率达88%，谈判成功率创近7 年新高，最高降幅94%，新版目录自2026 年1 月1 日起正式执行。12 月第2 周医药生物下跌1.04%，医疗研发外包板块涨幅最大从月度数据来看，2025 年初至今沪深整体呈现上行趋势。本周医药生物下跌1.04%，跑输沪深300 指数0.96pct，在31 个子行业中排名第17 位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978","01801","03933","01167","06160"],"gpt_icon":0},{"id":"2591652163","title":"医药生物行业2026年度投资策略报告：十年创新 踏出海征程","url":"https://stock-news.laohu8.com/highlight/detail?id=2591652163","media":"东方证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591652163?lang=zh_cn&edition=fundamental","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"全行业来看，2025 年前三季度营收同比-0.9%，归母净利润和扣非净利润分别同比-2.2%和-9.6%。小核酸药物正迎来适应症拓展和肝外递送系统的突破，商业化潜力有望爆发；体内CAR-T 正在获得MNC 高度认可，早期数据较为积极。医药行业创新产品集体涌现，国内需求明确，出海潜力充足。风险提示院内诊疗秩序出现重要不利干扰的风险；创新药新技术、新靶点、新产品关键临床失败的风险；全球生物医药行业投融资持续处于低谷的风险等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214133240a4492ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214133240a4492ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","HK0000165453.HKD","LU2097828805.USD","LU2097828631.EUR","LU2488822045.USD","03759","01801","BK1574","LU2242644610.SGD","LU1969619763.USD","LU0502904849.HKD","LU2097828714.EUR","BK1583","BK1161","LU2097828474.EUR","06127","06978","02359","LU0455707207.USD","LU2328871848.SGD","06160","LU2097828557.USD"],"gpt_icon":0},{"id":"2591637314","title":"一周药闻复盘|CPHI制药在线（2025.12.8-12.12）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591637314","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591637314?lang=zh_cn&edition=fundamental","pubTime":"2025-12-13 16:05","pubTimestamp":1765613111,"startTime":"0","endTime":"0","summary":"本周盘点包括审评审批、研发、交易及投融资以及上市四大板块，统计时间为2025.12.8-12.12，包含25条信息。申请11、12月9日，CDE官网显示，施贝康1类新药sbk002片申报上市，推测用于动脉粥样硬化血栓形成事件的二级预防。早在2023年5月，sbk002就向CDE递交过上市申请并获受理。2025年1月和6月，再次获批两项适应症。该药是全球首 个且目前唯一进入临床阶段的MUC18ADC，同时也是全球首 个进入临床的MUC18靶","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213160517a4468cfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213160517a4468cfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","01477","BK1574","09969","BK1191","02196","BK1588","BK1587","02696","01177","02607"],"gpt_icon":0},{"id":"2591639477","title":"和讯投顾冯禄顺：1213创新药接下来怎么走","url":"https://stock-news.laohu8.com/highlight/detail?id=2591639477","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591639477?lang=zh_cn&edition=fundamental","pubTime":"2025-12-13 15:26","pubTimestamp":1765610765,"startTime":"0","endTime":"0","summary":"12月13日，我们来解读一下创新药板块。创新药已经连续下跌好多天了，那么这个方向有没有可能在这个地方形成一个双底的结构呢？　　　　朋友们可以看到，创新药板块在经历了一波下跌之后，出现了反弹，现在又跌到了前期的低点附近。　　　　我之前给大家说过，创新药这个方向的反弹就是我们跑路的机会。　　　　今天，也就是周五，出现了一根金针探底的小阴线，探了一个底。　　　　所以，这个方向我们只能小反弹，谨慎参与。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20251213/31864360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2591639919","title":"青少年肥胖减肥难？本土创新药临床试验12周减重超8公斤","url":"https://stock-news.laohu8.com/highlight/detail?id=2591639919","media":"金羊网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591639919?lang=zh_cn&edition=fundamental","pubTime":"2025-12-13 14:53","pubTimestamp":1765608790,"startTime":"0","endTime":"0","summary":"玛仕度肽的临床数据青少年肥胖患者带来了解决方案。此次研究纳入了36名12-18岁的肥胖青少年，他们此前通过饮食运动干预12周后，BMI下降均不足5%，中位体重达95.83公斤，已属于中重度肥胖。12周后的结果显示，药物治疗组的减重效果显著。其中，4mg剂量组体重相对降低7.87%，平均减重7.72公斤；6mg剂量组效果更优，体重相对降低9.93%，平均减重8.65公斤，BMI分别较基线下降8.78%和10.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213145532a4466484&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213145532a4466484&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","LU2097828714.EUR","HK0000165453.HKD","LU2488822045.USD","01801","LU0455707207.USD","LU2097828631.EUR","LU2097828557.USD","LU1969619763.USD","BK1574","LU2097828474.EUR","LU2242644610.SGD","LU2097828805.USD","LU0502904849.HKD","06978","LU2328871848.SGD","BK1589"],"gpt_icon":0},{"id":"2591637659","title":"国内首款！沛嘉医疗新品获NMPA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591637659","media":"医疗器械商业评论","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591637659?lang=zh_cn&edition=fundamental","pubTime":"2025-12-13 10:24","pubTimestamp":1765592677,"startTime":"0","endTime":"0","summary":"随着专用于主动脉瓣反流的器械TaurusTrio获批上市，这一临床领域迎来了重要进展。张    一沛嘉医疗有限公司董事长兼执行董事今天，我们共同迎来一个重要里程碑：由沛嘉医疗自JenaValve引进并本土化的TaurusTrio经导管主动脉瓣系统，正式获得国家药品监督管理局批准上市。沛嘉医疗将全力推进TaurusTrio的临床应用，造福广大患者，并将持续携手全球创新力量，共同引领行业进步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213105152a4460a12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213105152a4460a12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1583","BK1100","BK1574"],"gpt_icon":0},{"id":"2591630613","title":"复星医药携手深圳理工大学共建AI驱动医药研发公共服务平台，项目获深圳市战略性新兴产业资助","url":"https://stock-news.laohu8.com/highlight/detail?id=2591630613","media":"复星医药官微","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591630613?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 23:15","pubTimestamp":1765552512,"startTime":"0","endTime":"0","summary":"近日，深圳市发展和改革委员会正式批复2025年第一批战略性新兴产业扶持计划，由复星医药大湾区总部联席CEO，复星医药AI委员会主任王兴利与深圳理工大学药学院院长陈有海领衔申报的“深圳市AI驱动医药研发公共服务平台组建项目”成功入选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212235443a445448a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212235443a445448a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02196","BK1191","09939","BK1593","BK1515","BK1161"],"gpt_icon":0},{"id":"2590507491","title":"心玮医疗-B(06609.HK)：取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2590507491","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590507491?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 23:07","pubTimestamp":1765552021,"startTime":"0","endTime":"0","summary":"格隆汇12月12日丨心玮医疗-B(06609.HK)公告，根据于2024年7月1日起施行的《中华人民共和国公司法》修正案(“新《公司法》”)，股份有限公司可以按照组织章程细则的规定设置由董事组成的审计委员会，行使新《公司法》规定的监事会的职权，不设监事会。于2025年12月12日，鉴于新《公司法》的规定，董事会决议并提议取消监事会，该事项完成后监事会的职权将由董事会审计委员会行使。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251212/31863645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06609","BK1100","BK1587","BK1574"],"gpt_icon":0},{"id":"1104035330","title":"心玮医疗-B拟以每股港币45.00配发及发行100万股国内股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1104035330","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104035330?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 22:40","pubTimestamp":1765550412,"startTime":"0","endTime":"0","summary":"心玮医疗-B拟以每股港币45.00配发及发行100万股国内股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","BK1100","06609"],"gpt_icon":0},{"id":"2591631174","title":"药明巨诺换帅，新管理层迎战CAR-T市场机遇与挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2591631174","media":"21世纪经济报道","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591631174?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 20:41","pubTimestamp":1765543270,"startTime":"0","endTime":"0","summary":"药明巨诺董事会在2025年9月批准的、拟授予刘敏的超420万份购股权，亦同步宣告取消。为保障管理过渡期间的运营稳定，药明巨诺表示，在田丰正式履职前，现有管理层将暂代行政总裁职责，确保公司日常运营平稳有序。新任董事会主席刘诚同样具备逾二十年行业深耕经验，药明巨诺公告称其在生物制药领域手握超300项专利及公开专利申请，在全球CAR-T领域专利排名中位居前列。药明巨诺管理层更换之际，正值国内CAR-T药物迎来商保支付的关键突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512122043399539f570&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512122043399539f570&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978","02126","BK1583"],"gpt_icon":0},{"id":"2590093905","title":"千亿美元出海“秀肌肉”、“首创”瓶颈“卡脖子”：中国创新药直面“仿创”转型考","url":"https://stock-news.laohu8.com/highlight/detail?id=2590093905","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590093905?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 20:32","pubTimestamp":1765542731,"startTime":"0","endTime":"0","summary":"对此，业内人士表示，该指数的发布，也让中国创新药产业更加“可评估、可对标、可引导”。业内人士表示，从“跟跑”到“引领”，中国创新药产业已行至中流击水处。千亿美元“出海”成绩彰显实力，制度破冰举措指明方向，但“首创”焦虑仍是必须直面的现实考题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212203214a69c0062&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212203214a69c0062&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2488822045.USD","LU1969619763.USD","LU0502904849.HKD","LU2097828805.USD","01530","LU2097828474.EUR","BK1583","BK1589","LU2242644610.SGD","02142","LU2097828557.USD","LU2097828714.EUR","BK1161","06978","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","BK1574","01801"],"gpt_icon":0},{"id":"1134872868","title":"沛嘉医疗-B获得NMPA批准，Taurustrio经导管主动脉瓣系统开创中国主动脉反流治疗新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134872868","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134872868?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 20:31","pubTimestamp":1765542676,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B获得NMPA批准，Taurustrio经导管主动脉瓣系统开创中国主动脉反流治疗新纪元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1100","09996"],"gpt_icon":0},{"id":"2590703505","title":"科济药业-B(02171)12月12日斥资389.45万港元回购25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590703505","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590703505?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 20:15","pubTimestamp":1765541718,"startTime":"0","endTime":"0","summary":"科济药业-B(02171)发布公告，于2025年12月12日斥资389.45万港元回购25万股。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_25.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_25.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","BK1587","BK1585","02171"],"gpt_icon":0},{"id":"2591636704","title":"同源康医药-B公布董事会成员名单及委员会任职情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2591636704","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591636704?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 18:28","pubTimestamp":1765535306,"startTime":"0","endTime":"0","summary":"金吾财讯 | 同源康医药-B于2025年12月12日公布董事会成员名单及其在董事会各委员会的任职情况。公告显示，公司董事会由1名执行董事、5名非执行董事及4名独立非执行董事组成。吴玉生博士担任科学委员会主席及提名委员会成员，冷雨婷博士担任薪酬及考核委员会主席及审计委员会成员，蒋晓林先生担任提名委员会主席及薪酬及考核委员会成员。其他董事亦在各委员会中担任相应职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121852569539c62a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121852569539c62a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1574","BK1515","02410"],"gpt_icon":0},{"id":"2590570816","title":"歌礼制药-B(01672)12月12日耗资约437.38万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590570816?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 18:21","pubTimestamp":1765534862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2025年12月12日耗资约437.38万港元回购30万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK1161","01672","01477","BK1515"],"gpt_icon":0},{"id":"2591633353","title":"耐赋康之后，谁接棒？云顶新耀为千亿市值铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=2591633353","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591633353?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 18:11","pubTimestamp":1765534287,"startTime":"0","endTime":"0","summary":"10月21日，云顶新耀在公司发展战略交流会上，明确提出要向千亿市值的目标发起冲击。此次合作是云顶新耀拓展新治疗领域的关键落子，也为其冲刺千亿市值的目标按下了“加速键”。这种“长坡厚雪”的赛道特性，对于云顶新耀而言，莱达西贝普的引进不仅是新增一款心血管产品，更对于其冲击千亿市值目标具有重要的战略价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212202120a69bfab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212202120a69bfab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"2590594570","title":"河南首家医药上市企业易主江西！获10亿元“输血”的太龙药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2590594570","media":"微博财经-财道工作室","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590594570?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 18:00","pubTimestamp":1765533600,"startTime":"0","endTime":"0","summary":"江药控股成立于2025年5月，尚无实际经营业务，其背后为江西省属医药龙头企业江药集团。调整后，太龙药业在2023—2025年累计净利润需不低于1.485亿元。但是截至2025年三季度末，太龙药业仅完成约1.19亿元，而太龙药业要在四季度狂揽近3000万元净利润才能履约，难度极大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2025-12-12/doc-inhapwff5587689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK0188","600222","159938","BK1161","BK1515","09939","BK0239"],"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":12,"totalSize":670,"code":"91000000","status":"200"}]}}